Clinical Trial Update: Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria [Phase 2]

View source ↗

Summary

A Phase 2 platform trial sponsored by Novartis is evaluating the efficacy and safety of multiple anti-malarial agents for uncomplicated Plasmodium falciparum ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uncomplicated Plasmodium Falciparum Malaria

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Status: RECRUITING